Please login to the form below

Not currently logged in
Email:
Password:

Charles River

This page shows the latest Charles River news and features for those working in and with pharma, biotech and healthcare.

Mid-sized European biotechs ‘need more support’

Mid-sized European biotechs ‘need more support’

In a new report commissioned by EFPIA and compiled by Charles River Associates (CRA), the authors were asked to explore the extent to which barriers to growth exist, and to what

Latest news

  • Galapagos divests CRO operations to pursue biotech path Galapagos divests CRO operations to pursue biotech path

    The company said the proceeds from the 134m deal with Charles River Laboratories would be used to progress a pipeline that includes the phase 2 JAK1 (Janus kinase 1)  inhibitor GLPG0634. ... The transition will be led by the CEO of Galapagos Services

  • Taking contract research’s pulse Taking contract research’s pulse

    James Foster, CEO of early-stage R&D-focused CRO Charles River Laboratories, has a different view, however, saying that the company currently makes around 25 per cent of its sales

  • Charles River ties up with Theorem for non-clinical testing

    CROs form strategic alliance in bioanalysis, immunogenicity and immunology. Charles River Laboratories and Theorem Clinical Research have formed a strategic alliance to provide their clients with a new non-clinical testing ... Alan Bartlett, executive

  • Solid Foundations

    But how do outsiders get a look in? Nathan Waller, a senior marketing manager with global CRO, Charles River Laboratories, believes the only thing stopping marketing from adopting a higher profile ... It is up to companies like Charles River and

  • BMS/ Gilead's Atripla for HIV approved in EU

    While at DLJ Merchant Banking Partners, the Avista partners were involved in numerous healthcare transactions including Accellent, Charles River Laboratories, Focus Diagnostics, KCI, NextPharma, Prometheus Labs, and Warner Chilcott.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    195+. Galapagos/ Charles River. Acquisition of CRO business. Drug discovery services business.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Galapagos decided to sell its BioFocus and Argenta drug discovery service divisions to Charles River during the month so that it could focus on being an R&D company and use

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Capitalising on new drug opportunities in mid-income countries

    Opportunities for new drugs in mid-income countries have come under the spotlight, following a survey by Charles River Associates (CRA), which says that more could be done to increase the

  • Charles River

    For more than 60 years, Charles River has provided tailored research models and laboratory animal support services, as well as preclinical and clinical support services, to help our global partners accelerate ... Telephone:800.3195.3430. Address:.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics